The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.
Thanks to The Cancer Genome Atlas (TCGA) Research Network, researchers now have a better understanding of genomic alternations in head and neck cancers.
The recent extended approval of ibrutinib for the treatment of Waldenström's macroglobulinemia (WM), the disease's first FDA-approved therapy, has provided new hope for patients with the orphan disease.
Part I of a series on these newly approved agents.
During President Barack Obama's State of the Union Address last week, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes. This morning he built on his announcement and outlined a $215 million plan to help develop precision medicine nationwide.
Women diagnosed with early-stage breast disease have a variety of decisions to make regarding their treatment options. For example, some women may be eligible for breast-conserving surgery, which typically includes a lumpectomy followed by radiation.
When motivating people to get screened for cancer, fear may not be the best way to do it.
Cancer Hope Network's TACT program incorporates clinical trials into the criteria that is considered when making those matches.
A new study has found that while the breast cancer prevention drug tamoxifen's benefits outweigh its risks, the drug isn't right for all women.
Few clinicians are asking about their use and most lack knowledge about them.
After many (ten!) marathon attempts over several (six!) years, I was able to reach my qualifying time for the Boston Marathon.
January is National Mentoring Month, a great time to spotlight the unique matching process whereby Imerman Angels partners individuals seeking cancer support with a "Mentor Angel."
2015 is starting off with a bang, with a focus on brain cancer patients and new treatment options for recurrent glioblastoma (rGBM).
The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
The first iteration of the American Society of Clinical Oncology's (ASCO's) endeavor to capture and harness big data, CancerLinQ, is scheduled for release in late 2015.
Each year, the American Cancer Society publishes its annual cancer statistics, highlighting gains as well as areas that need continued focus. For 2015, the organization's report shows a 22% decrease in cancer death over the past 20 years, equating to more than 1.5 million lives saved-a positive trend seen for the past few years.
With the number of cancer survivors expected to reach 19 million by 2024, how these individuals fare long-term is an issue of ongoing interest and concern. An analysis of findings from a large survey of survivors conducted by the American Cancer Society (ACS) has found that many survivors continue to face physical, mental, and financial difficulties long after their treatment ends.
Changing the administration schedule for gemcitabine plus nab-paclitaxel (Abraxane) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
Protective effect of tamoxifen continues after treatment stops.
This NCI-funded educational program will train cancer care clinicians over two years to develop, implement, and maintain comprehensive psychosocial distress screening programs.
Even though cancer technology and treatment have improved greatly over the years, patients are still wary of participating in first-in-human studies of potential new agents.
A new study has shown that postmenopausal women who had insulin abnormalities were at an increased risk for breast cancer regardless if they were overweight or normal-weight individuals.
Debbie's Dream Foundation is hosting a free webinar on nutrition and clinical trials
For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.
A "watch and wait" surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery, according to a retrospective review of clinical data presented at the 2015 Gastrointestinal Cancers Symposium.
Researchers from the Case Comprehensive Cancer Center have discovered new gene mutations that are unique to colon cancer in African American patients, who have the highest incidence and death rate from the disease.
Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment
Focus is often on physical, and not psychosocial, concerns.
Results of a phase II study showed that women with small, stage I HER2-positive tumors who received a combination of lower-intensity chemotherapy and the targeted drug trastuzumab following surgery were highly unlikely to have the cancer recur within 3 years
Part 2 of an overview and explanation of current cutaneous lymphoma treatments.
